Biobank for pancreatic adenocarcinoma research
Official title: Anatomical-Clinical Base of Adenocarcinoma Pancreatic
Run by University Hospital, Toulouse · NCT06128343 · Data updated 2026-11-12
This study is collecting samples and information from people with pancreatic cancer to help find better ways to diagnose and treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 8 sites (Béthune and 7 other locations) |
| Status | Recruiting |
| Started | November 16, 2023 |
| Main results expected | January 31, 2035 |
| Study ends | February 28, 2035 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT06128343 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a histologically or cytologically proven diagnosis of pancreatic adenocarcinoma or those with pancreatic mass syndrome undergoing specific imaging studies.
✕Probably not a fit
Patients with pancreatic tumors that are not adenocarcinomas or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
BACAP-2 is a prospective biobank focused on collecting clinical data and biological samples from patients with pancreatic adenocarcinoma. The study aims to enhance the existing BACAP collection to support future research projects aimed at improving diagnosis and treatment of pancreatic cancer. It addresses the challenges of timely diagnosis and the need for new therapeutic targets by analyzing fresh tumor tissue and somatic genetic data. The ultimate goal is to develop new diagnostic tools and understand tumor development and chemotherapy responses.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment options for patients with pancreatic adenocarcinoma.
How similar studies have gone: Other studies focusing on biobanks for cancer research have shown success in advancing understanding and treatment options, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or * Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or * Patient with pancreatic adenocarcinoma proven histologically and/or cytologically Exclusion Criteria: * Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma * Pregnant or breastfeeding patient
Where it's running
-
Rangueil hospital
Toulouse, France Recruiting -
Béthune hospital center
Béthune, France Not yet recruiting -
Haut-Lévêque Hospital
Bordeaux, France Not yet recruiting -
Huriez Hospital
Lille, France Not yet recruiting -
Jean Mermoz private hosptila
Lyon, France Not yet recruiting -
Saint Eloi Hospital
Montpellier, France Not yet recruiting
Show 2 more locations
-
Regional Cancer Center From Montpellier
Montpellier, France Not yet recruiting -
PAU hospital
Pau, France Not yet recruiting
Study contacts
- Principal investigator: Barbara BOURNET, MD, PhD — University Hospital, Toulouse
- Study coordinator: Barbara BOURNET, MD, PhD
- Email: bournet.b@chu-toulouse.fr
- Phone: (0)5 61 32 32 35
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
-
Improving treatment planning for recurrent colorectal cancer using MRI
This study is testing a new way to use MRI scans to help doctors plan better treatments for patients with recurrent colorectal cancer.
-
Using vorolanib for treating advanced kidney cancer
This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.
-
Treatment with STAR0602 for advanced solid tumors
This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.
-
Evaluating MRI and biopsy methods for prostate cancer detection
This study is testing whether a new type of MRI and a different way to do biopsies can help find prostate cancer more accurately in men who might have it.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.